Acumen Pharmaceuticals, Inc. (ABOS)
- Previous Close
1.0100 - Open
1.0000 - Bid 0.7704 x 200
- Ask 1.2900 x 200
- Day's Range
0.9960 - 1.0900 - 52 Week Range
0.8550 - 3.9200 - Volume
165,275 - Avg. Volume
220,469 - Market Cap (intraday)
64.814M - Beta (5Y Monthly) 0.09
- PE Ratio (TTM)
-- - EPS (TTM)
-1.9400 - Earnings Date Aug 11, 2025 - Aug 15, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
8.75
Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops targeted therapies for the treatment of Alzheimer's disease. The company focuses on advancing a targeted immunotherapy drug candidate Sabirnetug (ACU193), a recombinant humanized immunoglobulin gamma 2, which has completed the INTERCEPT-AD phase 1 clinical trial and in ALTITUDE-AD phase 2 clinical trial to target soluble amyloid-beta oligomers. It has a collaboration and license agreement with Halozyme, Inc. for the development of a subcutaneous formulation of Sabirnetug. Acumen Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in Newton, Massachusetts.
acumenpharm.comRecent News: ABOS
View MorePerformance Overview: ABOS
Trailing total returns as of 5/16/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: ABOS
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: ABOS
View MoreValuation Measures
Market Cap
64.81M
Enterprise Value
-55.33M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
0.42
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-31.31%
Return on Equity (ttm)
-55.68%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-116.25M
Diluted EPS (ttm)
-1.9400
Balance Sheet and Cash Flow
Total Cash (mrq)
149.15M
Total Debt/Equity (mrq)
19.15%
Levered Free Cash Flow (ttm)
-63.62M